Core Viewpoint - Haofan Bio (301393) reported that its overseas sales revenue for 2024 is projected to account for 22.13% from Asia, 10.04% from Europe, and 4.09% from America of the total operating revenue [1] Group 1: Company Overview - The main products of the company are specialty chemical raw materials primarily based on peptide synthesis reagents, positioned upstream in the pharmaceutical industry chain [1] - The company offers a wide range of products and serves thousands of customers annually, demonstrating strong risk resistance capabilities [1] Group 2: Market Expansion - The company established a wholly-owned subsidiary in Germany in January 2025, targeting CDMO and formulation clients in the European market to further expand its business in Europe [1]
昊帆生物：公司2024年度直接销往亚洲、欧洲、美洲的境外销售收入占公司营业收入总额的比例分别为22.13%、10.04%、4.09%